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Barriers to Biosimilar Approval: Creating 
Clarity Through the Publication of Product-
Class Specific Guidances 
MARTIN MCENRUE  
INTRODUCTION 
The European Union is far ahead the United States in creating a 
biosimilar market for its citizens. The Patient Protection and Afforda-
ble Care Act (PPACA)1, colloquially known as Obamacare, was en-
acted in 2010 and set out to create a health care plan for the uninsured 
in an attempt “to rein in rising costs of health care.”2 Within the 
PPACA is a section titled the Biologics Price Competition and Inno-
vation Act (BPCIA), which gave guidance for biosimilar approval.3 
Specifically, the Act had the intention of enumerating the requirements 
for biosimilar approval to create an easier process for the manufactur-
ers.4 Since the approval of the BPCIA, the United States and the Food 
and Drug Administration (FDA) have had difficulty in approving a bi-
osimilar product. As of December 2016, the FDA has only approved 
 
© 2016 Martin McEnrue 
 JD Candidate, 2017, University of Maryland School of Law.  I would like to thank Pro-
fessors Van Alstine and Danchin and the MJIL team for providing revisions and edits given 
in the process of writing this article.  I would also like to thank my parents for all of their 
support. 
 1.  42 U.S.C. §18001 (2010). 
 2.  Michael Levy, Patient Protection and Affordable Care Act (PPACA), ENCYCLOPEDIA 
BRITANNICA, http://www.britannica.com/topic/Patient-Protection-and-Affordable-Care-Act. 
 3.  Biosimilars: Questions and Answers Regarding Implementation of the Biologics 
Price Competition and Innovation Act of 2009, 80 Fed. Reg. 24259, 24260 (Apr. 30, 2015). 
 4.  Joanna M. Shepherd, Biologic Drugs, Biosimilars, and Barriers to Entry, 25 HEALTH 
MATRIX 139, 146 (2015) (stating that the “BPCIA provides an expedited biosimilar approval 
pathway”). 
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four biosimilars, Zarxio,5 Inflectra,6 Erelzi,7 and Amjevita.8 This is 
falling short to the European Medicines Agency (EMA), the European 
Union’s equivalent to the FDA, which has had much greater success 
in approving biosimilars. The EMA has approved 25 biosimilars, in-
cluding Zarzio, since 2006.9 The FDA should  follow the approach of 
the EMA by creating product-specific guidelines to create a biosimilar 
market in the United States.  
In this Comment, Part IA will define and provide the regulatory 
history of biosimilars in both the United States and European Union. 
Part IB will outline the current FDA approval process of biosimilars 
and Part IC will outline the approval process of the EMA. Part II of 
this Comment will discuss and analyze the major differences between 
the EMA’s and FDA’s methods of biosimilar approval. Part III will 
discuss how the FDA can adopt EMA methods to facilitate biosimilar 
approval and create a larger market.  
 
 5. FDA News Release, U.S. Food and Drug Admin., FDA Approves First Biosimilar 
Product Zarxio, (Mar. 6, 2015), http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm436648.htm. The approval of Zarxio was met with a lawsuit from the manufacturer 
of Neupogen, Amgen Inc., which claimed that Sandoz, Inc. violated California state law for 
unfair competition, conversion, and patent infringement.  The Federal Circuit Court ruled that 
Sandoz, Inc did not violate the BPCIA by failing to disclose its application and manufacturing 
information to Amgen, Inc. and did not violate California’s unfair competition or conversion 
statutes. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).  This case was granted 
certiorari by the Supreme Court on January 13, 2017.  Amgen Inc. v. Sandoz Inc., 794 F.3d 
1347 (Fed. Cir. 2015), cert. granted, 84 USLW 3455, U.S., Jan. 13, 2017. 
 6. On April 5, 2016, the FDA approved a second biosimilar named Inflectra with the 
reference product Remicade.  U.S. Food & Drug Administration, FDA approves Inflectra, a 
biosimilar to Remicade, U.S. FOOD AND DRUG ADMINISTRATION: PROTECTING AND PROMOTING 
YOUR HEALTH (Apr. 5, 2016), http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm494227.htm.  
 7.  On August 30, 2016 FDA approved its third biosimilar, Erelzi, (etanercept-szzs) for 
multiple inflammatory diseases, which is a biosimilar to Enbrel (etanercept). See U.S. Food & 
Drug Administration, FDA approves Erelzi, a biosimilar to Enbrel, U.S. FOOD AND DRUG 
ADMINISTRATION: PROTECTING AND PROMOTING YOUR HEALTH (Aug. 30, 2016), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm. 
 8. On September 23, 2016, FDA approved its fourth biosimilar, “Amjevita (ada-
limumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.” 
See U.S. Food & Drug Administration, FDA approves Amjevita, a biosimilar to Humira, U.S. 
Food & Drug Administration: Protecting and Promoting Your Health (Sep. 23, 2016), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm. 
 9. Generics and Biosimilars Initiative, Biosimilars approved in Europe, GABI ONLINE 
(Jan. 13, 2017), http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Eu-
rope; see also David Kroll, FDA Approves First US Biosimilar; Hold Your Breath on Cost 
Savings, FORBES (Mar. 6, 2015), http://www.forbes.com/sites/davidkroll/2015/03/06/fda-ap-
proves-first-us-biosimilar-zarxio-by-sandoz/#4ef2845c76c9. 
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I.  BIOSIMILAR APPROVAL 
A.  Background and Definitions 
Biological products are a difficult treatment class to define.10 The 
FDA chose to define biologics by listing the general categories which 
the treatments can be included under, providing that the treatment 
products are “a virus, therapeutic serum, toxin, antitoxin, vaccine, 
[etc.]11 . . . applicable to the prevention, treatment, or cure of a disease 
or condition of human beings.”12 Others use the differences between 
chemically created drugs and biologics to define the treatment class.13 
The two commonalties that most definitions share are that biologics 
are created from living organisms and that they are large, complex 
molecules.14 The influenza (flu) vaccine is an example of a biologic 
that is commonly used in the United States; it uses a safe version of the 
virus to treat and prevent the disease associated with the flu.15 Any 
product defined as a biologic and previously approved by FDA can be 
used as a reference product to a biosimilar product.16 The FDA defines 
biosimilarity to mean “that the biological product is highly similar to 
the reference product notwithstanding minor differences in clinically 
inactive components.”17 There cannot be any “clinically meaningful 
differences between the biological product and the reference product 
 
 10.  Thomas Morrow & Linda Hull Felcone, Defining the Difference: What Makes Bio-
logics Unique, BIOTECHNOLOGY & HEALTHCARE, Sept. 2004, at 24. 
 11.  The definition also includes blood, blood component or derivative, allergenic product 
or analogous, or arsphenamine or derivative of arsphenamine. U.S. FOOD & DRUG ADMIN., 
INVESTIGATIONS OPERATIONS MANUAL 290 (2016), http://www.fda.gov/down-
loads/ICECI/Inspections/IOM/UCM150576.pdf. 
 12.  Id. 
 13.  Morrow & Felcone, supra note 10, at 24.  This article uses the “two  critical traits 
that distinguish their physical makeup from chemically derived drugs: only living systems can 
produce them, and biologics are relatively large molecules, with an inherently heterogeneous 
structure that can contain hundreds of amino acids” as an example of a definition. Id. 
 14.  Id. 
 15.  Influenza (Flu): How Influenza (Flue) Vaccines Are Made, CTRS. FOR DISEASE 
CONTROL & PREVENTION (Jan. 6, 2015), http://www.cdc.gov/flu/protect/vaccine/how-fluvac-
cine-made.htm 
 16.  Information on Biosimilars, U.S. FOOD & DRUG ADMIN. (Feb. 22, 2016), 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAp-
proved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm.  
The biologic product must be approved by the FDA. Id. 
 17.  Leah Christl, FDA’s Overview of the Regulatory Guidance for the Development and 
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in terms of the safety, purity, and potency of the product.”18 For in-
stance, Zarxio, the first approved biosimilar in the United States, uses 
the biologic Neuopogen as its reference.19 Both of these products use 
filgrastim, a protein used to increase the number of white blood cells 
in cancer patients, as the active ingredient for treatment.20    
Under the current biosimilar framework, there are also require-
ments for an “interchangeable product,” which are much more specific 
than that of biosimilars in their similarity to the reference product. For 
a product to be interchangeable, it must be “biosimilar to the reference 
product; it can be expected to produce the same clinical result as the 
reference product in any given patient.”21 The FDA also includes that 
“[t]he interchangeable product may be substituted for the reference 
product without the intervention of the health care provider who pre-
scribed the reference product.”22 There are currently no approved in-
terchangeable products in the United States or Europe.   
There are many similarities between biosimilar products and ge-
neric drugs, most specifically their purpose and relation to the refer-
ence product. However, their differences are more significant. The 
Hatch Waxman Amendments of 1984 (Hatch Waxman)23 created the 
modern generic drug market.24 Although generic drugs were able to be 
approved before these amendments, they had to go through the same 
approval process as the listed drug they referenced.25 Hatch Waxman 
created the Abbreviated New Drug Application (ANDA), a new ap-
proval process specifically for generic drug manufacturers.26 This ap-
plication significantly shortens the length of time and lessens the cost 
 
 18.  Id. 
 19.  FDA News Release, supra note 5. 
 20.  Id.; Filgrastim, CHEMOCARE.COM, http://chemocare.com/chemotherapy/drug-
info/filgrastim.aspx. 
 21.  Christl, supra note 17, at 8. 
 22.  Id. 
 23.  The “Hatch-Waxman Amendments” refer to the Drug Price Competition and Patent 
Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984).  Statement of Daniel 
E. Troy, U.S. Food & Drug Admin., Drug Price Competition and Patent Term Restoration Act 
of 1984 (Hatch-Waxman Amendments), Aug. 1, 2003, http://www.fda.gov/newsevents/testi-
mony/ucm115033.htm. 
 24.  Statement of Daniel E. Troy, supra note 23. 
 25.  Id. The full approval process is costly and time consuming. Generic drugs having to 
complete the full process most likely increased the expense of the final generic drug once it 
entered the market and delayed the drug entering the market. Id. 
 26.  Id. In an ANDA, the generic drug manufacturer only has to show bioequivalence to 
the previously approved NDA and “relies on the Agency’s finding of safety and effectiveness 
of the listed drug product.” Id. 
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to develop a generic drug.27 This allows manufacturers to charge less 
for the drug and makes the drug accessible to more people.   
After Hatch Waxman, there was a great increase in the number of 
generic drugs on the market,28 as it was relatively easier to recreate a 
listed reference drug that was chemically manufactured in a lab.29 Be-
ing chemically created, the entire drug serves a purpose in the treat-
ment it is listed for.30 Biologics are different because they come from 
a live product that is not originally manufactured in a lab.31 Live bio-
logic products are much more complex than other pharmaceuticals.32 
The active ingredient for treatment may be just one of many compo-
nents found in the biologic.33 A biosimilar product must only replicate 
the active ingredient(s) in the reference product, as long as the other 
components are inactive.34 The major difference between drugs and bi-
ologics is the complexity of biologics, which biosimilar manufacturers 
must overcome in creating their product.   
B.  Biosimilars in the United States 
The approval process for biosimilar products is enumerated in the 
BPCIA, passed by Congress with the PPACA.35 The BPCIA amended 
42 U.S.C. § 262 by adding sections related to biosimilars and patents 
for biologic products.36 It also included information biosimilar manu-
facturers are required to provide to the FDA for approval, the Secre-
tary’s process of determining whether the product should be approved, 
and the exclusivity of the reference product.37 Also included within the 
 
 27.  Id. 
 28.  Id. A generic drug is defined as “[a] drug product that is comparable to a brand/ref-
erence listed drug product in dosage form, strength, route, administration, quality and perfor-
mance characteristics, and intended use.”  Ted Sherwood, Generic Drugs, U.S. FOOD & DRUG 
ADMIN., at 7, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Small-
BusinessAssistance/ucm127615.pdf. 
 29.  How Drugs Are Developed and Approved, U.S FOOD & DRUG ADMIN. (Aug. 18, 
2015), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevel-
opedandApproved. 
 30.  See, e.g., id. 
 31.  Shepherd, supra note 4, at 142. 
 32.  Id. 
 33.  Barbara Mounho et al., Global Regulatory Standards for the Approval of Biosimilars, 
65 FOOD & DRUG L.J. 819, 825 (2010). 
 34.  Christl, supra note 17, at 6. 
 35.  Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119. 
 36.  U.S. FOOD & DRUG ADMIN., SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING 
BIOSIMILARITY TO A REFERENCE PRODUCT: GUIDANCE FOR INDUSTRY 1 (2015). 
 37.  Id. 
MCENRUEFINALBOOKPROOF(DO NOT DELETE) 3/16/2017  4:33 PM 
316 MARYLAND JOURNAL OF INTERNATIONAL LAW [Vol. 31:311 
Act is a crucial section on future guidance documents related to bio-
similars.38 This section shows the intent of the FDA to develop rules 
and regulations related to biosimilars over time.39  
The FDA’s scientific requirements for approval of biosimilars 
were first enumerated in the BPCIA and then further developed 
through draft guidances. The FDA uses a stepwise approach to gener-
ate data with evaluation of residual uncertainty while evaluating the 
research compiled by the manufacturer of the biosimilarity to the ref-
erence product.40 The administration uses a totality-of-the-circum-
stances approach in evaluating applications.41 This approach is justi-
fied by the FDA in stating there is “no ‘one size fits all’ assessment.”42 
The FDA claims this benefits the sponsor of the biosimilar, allowing 
the administration’s scientists to evaluate the “various types of infor-
mation to provide an overall assessment that a biological product is 
biosimilar to [the] reference product.”43 It is then left to the discretion 
of these scientists to approve the product if the data received provides 
that the sponsor’s product is similar enough to the reference product to 
be approved.44 
The data that the FDA considers is developed by the manufacturer 
using analytical studies, animal studies, and clinical studies.45 The 
Guidance, Scientific Considerations in Demonstrating Biosimilarity to 
a Reference Product created the process that biosimilar manufacturers 
should follow.46 The analytical data is collected using two studies, the 
structural analyses and functional assays.47 In the structural analysis, 
the FDA requires that the expression of the biosimilar product  encodes 
the same primary protein structure as the reference product.48 This en-
sures the structure of the active protein in the biosimilar has the same 
structure as the active protein in the reference product.49 The functional 
 
 38.  42 U.S.C. § 262(k)(8) (2012); see e.g., U.S. Food and Drug Administration, Clinical 
Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Guid-
ance for Industry (Dec. 2016), http://www.fda.gov/downloads/Drugs/GuidanceComplian-
ceRegulatoryInformation/Guidances/UCM397017.pdf. 
 39.  Id. 
 40.  Christl, supra note 17, at 19. 
 41.  Id. 
 42.  Id. at 20. 
 43.  Id. The reference product must be licensed in the United States. Id. 
 44.  Id. 
 45.  42 U.S.C. § 262(k)(2)(A)(i)(I). 
 46.  U.S. FOOD & DRUG ADMIN., supra note 36, at 1.   
 47.  Id. at 9–10. 
 48.  Id. at 9. 
 49.  Id. (stating that the “sponsors should consider all relevant characteristics of the pro-
tein product . . .to demonstrate that the proposed product is highly similar to the reference 
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assays, another step in the analytical collection of data, evaluates the 
activity of the proteins in the product.50 These functional assays are 
used to provide data to show that the “biologic activity and potency of 
the proposed product are highly similar to those of the reference prod-
uct.”51 They are also used to complement the animal and clinical data 
to assess minor difference in structure between the reference and sim-
ilar products.52 
 Following the analytical studies, the biosimilar product must be 
tested in animal studies.53 The animal studies are required to demon-
strate biosimilarity and the results can be used to support the safety 
evaluation.54 The animal toxicity study is the first animal study that 
must be conducted.55 This study is conducted to address uncertainties 
in the safety of the product before the clinical trials begin.56 The man-
ufacturer can use this test to compare the degree of similarity with the 
reference product.57 Animal immunogenicity tests are also conducted 
for the purpose of assisting the interpretation of animal study results.58 
Differences in the animal immunogenicity “may reflect potential struc-
tural or functional differences between the two products.”59 The clini-
cal studies can begin once the animal studies are completed and show 
biosimilarity to the reference product. 
The FDA requires the sponsor of a biosimilar drug to conduct 
clinical trials to prove there are no meaningful differences between 
their product and the reference product.60 First, a human pharmacology 
and clinical immunogenicity assessment must be conducted before the 
 
product”). 
 50.  Id. at 10 (stating that the functional assays can be either in vivo, in vitro, or both). 
 51.  Id. at 11. 
 52.  U.S. FOOD & DRUG ADMIN., supra note 36. 
 53.  Id. 
 54.  Id. 
 55.  Id.  
 56.  Id.  The FDA states this may contribute to the totality of the evidence that supports a 
demonstration of biosimilarity. Id. at 13. 
 57.  Id. at 12. 
 58.  Id. at 13. These studies, in contrast with their name, typically do not predict potential 
immune responses. Id. 
 59. U.S. FOOD & DRUG ADMIN., supra note 36. 
 60.  Id. 
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clinical trials begin.61 The human pharmacology assessment uses a jus-
tifiable62 human population to conduct pharmacokinetic63 and pharma-
codynamic64 profiles.65 The clinical immunogenicity assessment’s pur-
pose is to compare and evaluate the differences in incidence and 
severity of human immune responses.66 The sponsor should demon-
strate that there are no meaningful differences in immune response 
with the reference product while conducting their study.67 The popula-
tion for this study must be justified and agreed to by the Agency and a 
follow-up evaluation is required.68 The study “should consider . . . the 
immune response . . . , the clinical relevance and severity of conse-
quences . . . , the incidence of immune responses, and the population 
being studied.”69     
Comparative Clinical Studies are conducted to support a demon-
stration of biosimilarity to the reference product if there is uncertainty 
after the prior tests.70 When a sponsor decides it is necessary to conduct 
a comparative clinical study, they must provide a scientific justifica-
tion for the factors they choose to determine what type of clinical study 
they will conduct.71 The sample size and duration of the study should 
be “adequate to allow for the detection of clinically meaningful differ-
ences” with the reference product72 and the study “should be designed 
to investigate whether there are clinically meaningful differences” with 
the reference product.73 The clinical study should establish evidence 
 
 61.  Id. at 14. 
 62.  Sponsor must provide the FDA with reasoning as to why it chose specific groups 
(patients vs. healthy subjects) of people to be involved in the clinical trial. Id. 
 63.  Pharmacokinetic profiling analyzes “how the body affects the drug.” Garth T. White-
side & Jeffrey D. Kennedy, Consideration of Pharmacokinetic Pharmacodynamic Relation-
ships in the Discovery of New Pain Drugs, in TRANSLATIONAL PAIN RESEARCH: FROM MOUSE 
TO MAN (L. Kruger & A.R. Light eds., 2010). 
 64.  Pharmacodynamic profiling analyzes “how the drug affects the body.” Id. 
 65.  Id. In selection of the human population, the sponsor must consider the relevance and 
sensitivity of such population and parameters. Id. 
 66.  U.S. FOOD & DRUG ADMIN., supra note 36, at 16. It is recommended for the sponsor 
to collect immunogenicity data in all clinical studies. Id. 
 67.  Id. at 13 
 68.  Id. at 17. The follow-up period is recommended to be one year. Id. 
 69.  Id. at 16. 
 70.  Id. at 18. A sponsor must justify the reason for not conducting comparative clinical 
studies. Id. 
 71.  Id. at 19. 
 72.  U.S. FOOD & DRUG ADMIN., supra note 36, at 16.. The adequacy is determined on the 
endpoint that the study is focused on. Certain endpoints call for smaller sample sizes than 
others. Id. 
 73.  Id. at 20. The FDA expects studies designed to establish statistical evidence that the 
proposed product is neither inferior or superior to the reference product. 
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“that the proposed product is neither inferior” nor superior to the ref-
erence product.74 The FDA strongly suggests having multiple meetings 
with the sponsor during the biosimilar manufacturing process.75 For 
instance, meeting with the FDA at the beginning of the process is very 
important so that FDA can establish a “schedule of milestones that will 
serve as landmarks for future discussions with the Agency.”76 Once the 
sponsor has completed the comparative clinical studies, they can sub-
mit their data to the FDA for approval. 
The sponsor must submit a 351(k) application with the FDA in 
order to seek approval for a biosimilar product.77 The 351(k) applica-
tion requires the sponsor to show the similarity between their product 
and the reference product. To show this, the sponsor is required to 
show that the product: 1) is biosimilar to the reference product; 2) uti-
lizes that same mechanisms of action for the proposed condition of use; 
3) condition of use proposed in labeling have been previously ap-
proved for the reference product; 4) has the same route of administra-
tion, dosage form, and strength as the reference product; and 5) is man-
ufactured, processed, packed, or held in a facility that meets standards 
designed to assure that the biological product continues to be safe, 
pure, and potent.78 The Public Health Service Act (PHSA) mandates 
that all necessary information is derived from analytical studies, ani-
mal studies, and clinical studies.79 The FDA will license the biological 
product if they determine that the information submitted is sufficient 
to show that the product is either biosimilar or interchangeable to the 
reference product.80 The applicant must also consent to inspection of 
the facility where the product was manufactured to receive a license.81 
The reference product must have four years or more on the market be-
fore a biosimilar manufacturer can submit a 351(k) application and the 
application will not be made effective until twelve years after the ref-
erence product was first licensed.82 
C. Biosimilars in the European Union 
In Europe, the EMA regulates biosimilars through Directive 
 
 74.  Id.  
 75.  Id. at 23. 
 76.  Id. 
 77.  Christl, supra note 17, at 9. 
 78.  Id. 
 79.  Id. at 10. 
 80.  Id. at 11. 
 81.  Id. 
 82.  42 U.S.C. 262(k)(7) (2010). 
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2001/83/EC and Directive 2004/27/EC.83 The 2004 Directive amend-
ment provided a general explanation of biosimilar requirements, only 
providing three sentences on the topic.84 The amendment requires bio-
similar manufacturers to provide information with respect to the dif-
ferences between the biosimilar and the reference product.85 The EMA 
released three guidelines following the Directives, explaining in more 
detail the requirements for biosimilar approval including an overarch-
ing guideline containing greater detail than the legislation.86 The EMA 
has used the guideline method of regulating biosimilar approval to cre-
ate a thriving market with twenty-five different biosimilars.87 
The Directive 2004/27/EC amendments created the EMA ap-
proval process for biosimilar products and was further elaborated in 
subsequent guidelines.88 The European approval process is distinct 
from the United States’ because these guidelines enumerate separate 
steps to approval for each biologic product-type.89 The EMA has re-
leased eight product-specific guidelines for biosimilars which include 
guidelines for recombinant follicle-stimulating hormone, interferon 
beta, monoclonal antibodies, and recombinant erythropoietins.90 This 
method gives a very specific process for manufacturers to follow.   
 
 83.  Biosimilars in the EU, GENERIC PHARMACEUTICAL ASS’N, 
http://www.gphaonline.org/gpha-media/gpha-resources/biosimilars-in-the-eu (last visited on 
Apr. 4, 2016). 
 84.  Council Directive 136/34, art. 10, 2004 J.O. (L136) 4 (EC). “Where a biological me-
dicinal product which is similar to a reference biological product does not meet the conditions 
in the definition of generic medicinal products, owing to, in particular, differences relating to 
raw materials or differences in manufacturing processes of the biological medicinal product 
and the reference biological medicinal product, the results of appropriate pre-clinical tests or 
clinical trials relating to these conditions must be provided.  The type and quantity of the rel-
evant criteria stated in Annex I and the related detailed guidelines.  The results of other tests 
and trials from the reference medicinal product’s dossier shall not be provided.” Id. 
 85.  Id. 
 86.  Guideline on Similar Biological Medicinal Products, EUROPEAN MEDS. AGENCY, 
CHMP/437/04, Oct. 2005.  See also, Guideline on Similar Biological Medicinal Products Con-
taining Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Is-
sues, EUROPEAN MEDS. AGENCY, EMEA/CHMP/BMWP/42832/2005 Rev1, Dec. 2014.  See 
also, Guideline On Similar Biological Medicinal Products Containing Biotechnology-Derived 
Proteins as Active Substance: Quality Issues (revision 1), EUROPEAN MEDS. AGENCY, 
EMEA/CHMP/BWP/247713/2012 (May 2014). 
 87.  Generics and Biosimilars Initiative, Biosimilars approved in Europe, GABI ONLINE 
(Jan. 13, 2017), http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Eu-
rope. 
 88.  Council Directive 136/34, supra note 84. 
 89.  Guideline on Similar Biological Medicinal Products, supra note 86. 
 90.  Multidisciplinary: Biosimilar, EUROPEAN MEDS. AGENCY (2016), 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con-
tent_000408.jsp. 
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Following the Directive 2004/27/EC amendments creating the ap-
proval process, the general requirements for biosimilar approval were 
established in three guidelines.91 First, the Guideline of Similar Bio-
logical Medicinal Products outlined the basic principle to be applied to 
biosimilar products.92 In this guideline, the EMA describes the differ-
ence between biological products and other drugs and the difficulties 
in creating similar products to biologics.93 The guideline also requires 
that manufacturers of biosimilar products meet the EMA standards for 
quality, safety, and efficacy.94 The guideline requires that the reference 
product be used for comparative quality, safety, and efficacy studies.95 
The active substance must be similar to the reference product on a mo-
lecular and biological level.96 The pharmacological form, strength, and 
route of administration should also be the same as the reference prod-
uct’s, and, if it is not the same, the difference must be justified by ap-
propriate studies on a case-by-case basis.97  
The second guideline addresses quality issues for biosimilars and 
provides the requirements for comparability testing against the refer-
ence product.98 During a comparability test, the safety and efficacy of 
the biosimilar product are considered and assessed for implications 
against safety or efficacy of the reference product. The guidance lists 
considerations for the comparability test to assure the quality of the 
product.99 These considerations take into account the suitability of 
available analytical methods, validation of analytical methods, physi-
cochemical properties, biological activity, and purity and impurities.100 
The comparability test applies to both the level of medicinal properties 
and the active substances.101 
 
 91.  Biosimilars in the EU, GENERIC PHARMACEUTICAL ASS’N 2013, supra note 83. 
 92.  Guideline on Similar Biological Medicinal Products, supra note 88. 
 93.  Id. at 4. 
 94.  Id. at 3. 
 95.  Id. at 4. 
 96.  Id. at 5. For example, the similar biological product must have the same active com-
ponent as the reference product and not just a version of the active component. Id. 
 97.  Id. 
 98.  Guideline on Similar Biological Medicinal Products Containing Biotechnology-De-
rived Proteins as Active Substance: Quality Issues, EUROPEAN MEDS. AGENCY, 
EMEA/CHMP/BWP/49348/2005, 3 (Feb. 2006). 
 99.  Id. at 5. 
 100.  Id. at 6–7. 
 101.  Kuala Lumpur, Biosimilars in the European Union—Regulatory Perspectives, 
EUROPEAN MEDICINES AGENCY: SCIENCE, MEDICINES, HEALTH, 25 (May 30–31, 2011), 
http://www.ich.org/fileadmin/Public_Web_Site/Train-
ing/ASEAN_Q5C_workshop_May_2011/SESSION_IVa_Biosimilars.pdf. 
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The third guideline provides non-clinical and clinical data re-
quirements in biosimilar approval.102 Non-clinical data should be col-
lected, from both in vitro studies and in vivo studies, before initiating 
clinical studies.103 In vitro studies, typically cell-based assays or recep-
tor-binding assay studies, “establish comparability in reactivity and the 
likely causative factor(s) if comparability cannot be established.”104 
The in vivo studies are performed in animals and are designed to max-
imize the information obtained before beginning clinical studies.105 
Once the non-clinical data is collected, the manufacturer can begin the 
clinical studies. 
The purpose of the clinical studies is to produce comparable clin-
ical data to the reference product.106 This process is conducted in a step-
wise procedure beginning with “pharmacokinetic (PK) and phamaco-
dynamic (PD) studies followed by clinical efficacy and safety trials.”107 
In regards to biosimilars, the PK test is “is used to detect possible dif-
ferences in the interaction with the body between the originator and the 
biosimilar.”108 The PD studies concern the “magnitude and time course 
of the observed pharmacological effect.”109 The markers for the PD test 
should be selected to demonstrate the efficiency of the product and the 
efficiency of the test should be compared in a population where the 
possible differences between the reference product and biosimilar 
product can best be observed.110 These two studies can be combined in 
situations where certain requirements are met.111   
Efficacy and safety trials can begin once the PK and PD studies 
 
 102.  European Medicines Agency, Guideline on Similar Biological Medicinal Products 
Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical 
Issues, EMEA/CHMP/BMWP/42832/2005, 3 (Feb. 2006). 
 103.  Id. at 4. 
 104.  Id. 
 105.  Guideline on Similar Biological Medicinal Products Containing Biotechnology-De-
rived Proteins, supra note 86, at 4. These endpoints include pharmacodynamic effect, non-
clinical toxicity, and any safety concerns. Id. 
 106.  Id. at 5. 
 107.  Id.  
 108.  Id. at 8. 
 109.  Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development 
of Antibacterial Medicinal Products, EUROPEAN MEDS. AGENCY, CPMP/EWP/2655/99, 1 (July 
2000). 
 110.  Guideline of Similar Biological Medicinal Products Containing Biotechnology-De-
rived Proteins, supra note 86, at 5–6. 
 111.  Id. at 5–6. These requirements include if the PK of the reference medicinal product 
are well characterized; there is sufficient knowledge of the pharmacodynamics properties of 
the reference medicinal product; the relationship between dose/exposure and response/effi-
cacy of the reference medicinal product is sufficiently characterized; and at least one PK 
marker is accepted as a surrogate marker for efficacy. Id.  
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are completed and shown to have similar results to the reference prod-
uct.112 The efficacy trials are necessary to demonstrate further the com-
parable clinical effects of the biosimilar product and reference prod-
uct.113 Once the biosimilar is shown to be effective, safety tests are still 
necessary before the product can be approved.114 These studies obtain 
data from a number of patients to address adverse events compared to 
the reference product.115 The immunogenicity of the product is ob-
served and considered throughout the process, and if an applicant has 
an immune response different from the reference product, further anal-
ysis must be conducted for clinical safety, efficacy, and PK parame-
ters.116 These are the general requirements in the EMA for similar bio-
logic products, with more specific requirements found in further 
guidelines tailored to each biologic product. 
For biosimilar approval in the European Union, the sponsor must 
follow the same marketing application process as other drugs in addi-
tion to the biosimilar specific requirements.117 For a normal drug mar-
keting application with the EMA, the applicant must include the name 
of the medicinal product, name of the active substance, and pharma-
cotherapeutic group.118 The strength of the product, pharmaceutical 
form, route of administration, container, and pack sizes must also be 
included.119 The legal status of the product and whether it is subject to 
medical prescription is also required on the application.120  
The EMA has created five modules in the organization of their 
application specific to biosimilar approval.121 Module 1 requires the 
sponsor to provide a “concise document summarizing the grounds and 
evidence used for demonstrating that the medicinal product for which 
an application is submitted is a similar biologic medicinal product.”122 
 
 112.  Id. at 6. 
 113.  Id. 
 114.  Id. 
 115.  Id. at 6. Assuming the reference product has adverse effects, the similar biologic 
should be expected to have a similar rate of these effects. Id. 
 116.  Id. at 7.  
 117.  Notice to Applicants: Volume 2B-CTD, 12 (June 2006). 
 118.  European Commission: Health and Consumers Directorate-General, Medicinal Prod-
ucts for Human Use: Volume 2B: Module 1.2: Administrative Information Application Form, 
Revision 12, EUROPEAN MEDS. AGENCY, 1 (Sept. 2015). 
 119.  Id. at 17–18. 
 120.  Id. at 19–20. 
 121.  Q&A 11-20: Similar Biological Product Application, EUROPEAN MEDS. AGENCY, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_de-
tail_000126.jsp&mid=WC0b01ac0580533e0d (last visited Apr. 7, 2016). 
 122.  Id. 
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The summary should include the active substance and differences be-
tween the relevant attributes of the reference medicinal product. In 
showing the data, “the comparability exercise versus the reference me-
dicinal product for quality, safety and efficacy should be described and 
the reference medicinal product . . . defined.”123 Module 2 requires the 
overall summary of the quality study and clinical and nonclinical over-
views.124 Module 3 should include the regular requirements for medic-
inal product marketing approval along with a demonstration of com-
parability to the reference product.125 This section should include 
information about “Facilities and Equipment and Safety Evaluation of 
Adventitious Agents” and the origin of animals used.126 Module 4 and 
Module 5 provide that “results of pre-clinical and clinical studies 
should be provided.”127 If any confusion in the application process ex-
ists, the EMA allows applicants to set up meetings to have the confu-
sion clarified.128   
II. DIFFERENCES BETWEEN THE BIOSIMILAR APPROVAL PROCESSES 
Even though the pathways for approval look similar, the success 
of the biosimilar program in the EU proves that there are still differ-
ences between the EMA and FDA. Two major differences in the pro-
grams are relevant to this issue: FDA’s emphasis on sponsor meetings 
during the development stage129 and the EMA’s product-specific 
guidelines.130 These differences show the contrasting approaches that 
each agency takes with respect to biosimilars. Overall, the FDA takes 
a broad regulatory approach and, through meetings, attempts to advise 
and facilitate the sponsor’s development.131 The EMA has given 
greater regulatory guidance for biosimilar development, through prod-
uct class-specific guidelines.132 The sponsors are aware of what is re-
quired for their product to be approved through these guidelines and 
 
 123.  Id. 
 124.  Id. 
 125.  Id. 
 126.  Q&A 11-20: Similar Biological Product Application, EUROPEAN MEDS. AGENCY, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_de-
tail_000126.jsp&mid=WC0b01ac0580533e0d (last visited Apr. 7, 2016). 
 127.  Id. 
 128.  Id. 
 129.  Food and Drug Admin., U.S. Dep’t of Health and Human Serv., OMB Control No. 
0910-0802, Formal Meetings Between FDA and Biosimilar Biological Product Sponsors or 
Applicants: Guidance for Industry, 1–2 (Nov. 2015). 
 130.  Multidisciplinary: Biosimilar, supra note 90. 
 131.  See generally OMB Control No. 0910-0802, supra note 129. 
 132.  Jun Wang & Shein-Chung Chow, ON the Regulatory Approval Pathway of Biosimi-
lar Products, 5 PHARMACEUTICALS 353, 360 (May 30, 2012). 
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therefore require less agency intervention. The FDA’s hands-on ap-
proach to biosimilar approval appears to be less effective in approving 
biosimilar products compared to the EMA’s regulatory guideline ap-
proach. 
The FDA created five different formal meetings in the Biosimilar 
User Fee Act of 2012 for sponsors of biosimilar products being devel-
oped.133 The sponsors of biosimilars are required to be a member of the 
Biosimilar Product Development (BPD) Program, a program created 
by the FDA, to request and participate in these meetings.134 
These meetings start with an initial meeting to determine if a li-
censure under section 351(k) may be feasible.135 The BPD Type 1 
meeting is only necessary if the biosimilar development has stalled for 
either safety reasons or clerical mistakes.136 This meeting allows the 
FDA to discuss how the sponsor can recover and what additional in-
formation is required to advance the approval process.137 BPD Type 2 
meetings target a specific issue or questions regarding an ongoing BPD 
program which the FDA can respond with targeted advice.138 BPD 
Type 3 meetings are the most important for application approval. Dur-
ing the Type 3 meeting, the FDA conducts a substantive review of full 
study reports and includes information regarding the similarity be-
tween the biosimilar product being developed and the reference prod-
uct and advice on additional studies needed.139 BPD Type 4 meetings 
are held to discuss the content of the application140 and are used to pre-
pare the sponsor for submitting their application for approval.141   
Though the BPD program appears to be a voluntary program cre-
ated to benefit the biosimilar manufacturers, the totality of the evi-
dence requirement for biosimilar approval, placed in the discretion of 
FDA scientists, makes it less beneficial.142 The BPD program requires 
 
 133.  Biosimilar Implementation: A Progress Report from FDA Before the S. Committee 
on Health, Education, Labor, and Pensions, 114th Cong. (Sept. 2015) (statement of Dr. Janet 
Woodcock, Dir., CDER of FDA). 
 134.  OMB Control No. 0910-0802, supra note 129, at 5. 
 135.  Id. at 3. 
 136.  Id. 
 137.  Id. 
 138.  Id. at 4. 
 139.  Id. 
 140.  Id. 
 141.  FDA Finalizes Guidance for Biosimilars Meetings, GENERICS & BIOSIMILARS 
INITIATIVE (Jan. 29, 2016), http://www.gabionline.net/Guidelines/FDA-finalizes-guidance-
for-biosimilars-meetings. 
 142.  There are very few resources referencing the effects of the meeting requirements for 
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its members to pay an annual user fee.143 As of December 2015, the 
annual fees are $237,420144 an amount that many generic drug compa-
nies find excessive.145 If the biosimilar sponsor were to fall behind on 
these fees, the FDA is able to deny a meeting.146 Also, scheduling the 
meetings with the FDA is a long process.147 In the final guidance, re-
leased in November 2015, the FDA created timelines for when meet-
ings should be scheduled following the submission of a request.148 Prior 
to the release of this final guidance, other manufacturers complained 
that the draft guidance released by the FDA was in need for clarifica-
tion and further detail.149   
Since the totality-of-the-evidence approach focuses on “review-
ing everything known about the applicant’s and the innovator’s prod-
ucts,” partaking in the BPD meetings greatly increases the chances of 
approval.150 Currently, there is no information on whether the final 
guidance improved the biosimilar approval process for sponsors, 
though there have been no biosimilars approved within the three 
months following the release of the guidance.151 Instead of expediting 
 
biosimilars, and none following the release of the Final Guidance for Formal Meetings Be-
tween the FDA and Biosimilar Product Sponsors. See generally, Call for Clarity in FDA’s 
Draft Guidance on Biosimilar Meetings, GENERICS & BIOSIMILARS INITIATIVE (June 2013), 
http://www.gabionline.net/Biosimilars/General/Call-for-clarity-in-FDA-s-draft-guidance-on-
biosimilar-meetings. 
 143.  OMB Control No. 0910-0802, supra note 129, at 5. 
 144.  Biosimilar User Fee Act (BsUFA), U.S. FOOD & DRUG ADMIN. (Dec. 30, 2015), 
http://www.fda.gov/ForIndustry/UserFees/BiosimilarUserFeeActBsUFA/default.htm. 
 145.  Call for Clarity in FDA’s Draft Guidance on Biosimilar Meetings, GENERICS & 
BIOSIMILARS INITIATIVE (June 2013), http://www.gabionline.net/Biosimilars/General/Call-
for-clarity-in-FDA-s-draft-guidance-on-biosimilar-meetings.  The generics company, Mylan, 
believes the user fees should be less than the fees required by PDUFA. Id. 
 146.  OMB Control No. 0910-0802, supra note 129, at 9. 
 147.  Call for Clarity in FDA’s Draft Guidance on Biosimilar Meetings, GENERICS & 
BIOSIMILARS INITIATIVE (June 2013), http://www.gabionline.net/Biosimilars/General/Call-
for-clarity-in-FDA-s-draft-guidance-on-biosimilar-meetings.  During the notice and comment 
period of the draft guidance, the drug manufacturer, Apotex, complained about the length of 
time the FDA takes to grant a meeting request. Id.  
 148.  Zachary Mietus, Formal Meetings with the FDA Regarding Biosimilars: What’s 
Changed, WEINBERG GROUP (Nov. 24, 2015), http://weinberggroup.com/formal-meetings-
with-fda-biosimilars. Type 1 meetings should be scheduled within 30 days, Type 2 should be 
scheduled within 75 days, Type 3 should be scheduled within 120 days, and Type 4 should be 
scheduled within 60 days.  Id. 
 149.  Call for Clarity in FDA’s Draft Guidance on Biosimilar Meetings, GENERICS & 
BIOSIMILARS INITIATIVE (June 2013), http://www.gabionline.net/Biosimilars/General/Call-
for-clarity-in-FDA-s-draft-guidance-on-biosimilar-meetings.   
 150.  Brian J. Malkin, Challenges to the Development of a Biosimilars Industry in the 
United States, in RECENT DEVELOPMENTS IN FOOD AND DRUG LAW 83, 83 (2013 ed). 
 151.  Biosimilars, U.S. FOOD & DRUG ADMINISTRATION, http://www.fda.gov/Drugs/Devel-
opmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/Ther-
apeuticBiologicApplications/Biosimilars (last visited on Apr. 6, 2016) (showing that the most 
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the manufacturing process, these meetings cause the process to stall or 
take longer than needed.152 This puts greater costs on sponsors of bio-
similars which could have gone to the development of the medical 
product. 
Instead of creating a system of voluntary meetings for the biosim-
ilar sponsors, the EMA decided to put the information necessary for 
development in their guidelines. As of September, 2015, the EMA has 
published ten final biological product class-specific guidelines.153 The 
complexity and diversity of biological product-classes necessitates a 
variety of different guidelines specific to each product.154 These classes 
vary in their “benefit/risk profile, the nature and frequency of adverse 
events, the breadth of clinical indications, and whether surrogate mark-
ers for efficacy are available and validated.”155 In creating the guide-
lines, “robust and thoughtful scientific discussion and deliberation 
drove decision-making.”156 The comments for the guidelines include a 
wide variety of interested groups such as the scientific community, 
pharmaceutical manufacturers and patient organizations.157 An exam-
ple of a class specific guideline is the Guidance on Similar Medicinal 
Products Containing Recombinant Granulocyte-Colony Stimulating 
Factor.158 This guideline gives specific requirements for the pharma-
codynamic studies, toxicological studies, and clinical studies.159 By 
making clear what is necessary for biosimilar sponsors to gain ap-
proval and licensure, they are able to focus more on the manufacturing 
of the biosimilar and will need less information from the agency re-
garding the manufacturing and approval process. 
The FDA’s method may appear to be effective but is slowing the 
approval process down. Instead of creating general guidances and try-
ing to meet and individually address the issues of the sponsors, the 
FDA should take the EMA’s approach and create biological product-
 
recently mentioned biosimilar is Zarzio, the first biosimilar approved). 
 152.  See Mietus, supra note 148 (including length of approval for each meeting type). 
 153.  Multidisciplinary: Biosimilar, supra note 90. 
 154.  Wang & Chow, supra note 132, at 360. 
 155.  Id.  
 156.  Barbara Mounho et al., Global Regulatory Standards for the Approval of Biosimilars, 
65 FOOD & DRUG L.J. 819, 822 (2010). 
 157.  Id. 
 158.  See generally European Meds. Agency, EMEA/CHMP/BMWP/31329/2005, Guid-
ance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulat-
ing Factor (Feb. 22, 2006). G-CSFs are proteins that bind to cells to carry out specific reac-
tions. generally European Meds. Agency, EMEA/CHMP/BMWP/31329/2005, Guidance on 
Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor 
(Feb. 22, 2006) 
 159.  Id. at 4–5. 
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class specific guidances.160 This method gives the sponsors clear re-
quirements necessary for approval and licensure of their product.161 
Clear and enumerated requirements may lead to an increase in the 
number of biosimilar approvals by the FDA. 
III. WAYS TO OVERCOME THESE BARRIERS 
The FDA is still able to make improvements to the biosimilar 
market, even though many problems in the market are caused by out-
side sources. One area that was proven to be most effective in helping 
create a biosimilar market is the publishing of product-type specific 
guidances.162 If the FDA was to follow the EMA’s guidance driven ap-
proach, sponsors will know what is expected to achieve biosimilar li-
censure approval.163 The FDA has been resistant to creating product-
specific guidances for biosimilars, believing that applicants should not 
be required to perform the same analytical, preclinical, and clinical 
testing.164 The FDA’s reluctance to create product-specific guidances 
has made it more difficult for biosimilars to be approved in the United 
States and has delayed the access to these drugs to the people of the 
United States.   
The FDA’s current approach of having general guidances with the 
purpose of having meetings with biosimilar sponsors has cost these 
sponsors more time and money.165 Creating a personalized method of 
biosimilar development through agency meetings with the product 
manufacturers appears to be ideal, but without the resources does not 
work. Instead, the FDA should adopt the EMA’s approach of having 
individual guidances for each biological product-class.166 This method 
has been called the gold standard for biosimilar approval and has been 
 
 160.  See Wang & Chow, supra note 132, at 360. The EMA’s guideline driven biosimilar 
approval process is considered to be the “gold standard” for authorizing biosimilar products. 
Id. 
 161.  See id. 
 162.  Id. The EMA approval process is called the “gold standard for authorizing biosimilar 
products.” 
 163.  See Vinita Banthia, Note, Biosimilar Regulation: Bringing the United States up to 
Speed with Other Markets, 16 MINN. J.L. SCI. & TECH. 879, 890–891 (2015). 
 164.  Malkin, supra note 150, at 9. 
 165.  See Call for Clarity in FDA’s Draft Guidance on Biosimilar Meetings, supra note 
145. 
 166.  An example is the Guidance on Similar Medicinal Products Containing Recombinant 
Granulocyte-Colony Stimulating Factor.  This Guideline led to the approval of Zarzio in 2009, 
the European Union equivalent of Zarxio.  EUROPEAN MEDS. AGENCY, 
EMEA/CHMP/BMWP/31329/2005, Guidance on Similar Medicinal Products Containing Re-
combinant Granulocyte-Colony Stimulating Factor (June 2006). 
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copied by other governing bodies including the World Health Organi-
zation.167 By only publishing general guidances, the FDA is creating 
more confusion for biosimilar developers. If the FDA were to start 
publishing more specific guidances related to product-class biosimi-
lars, the biosimilar sponsors will have more clarity and will be able to 
expedite their development process.168 
The FDA would not have to eliminate the totality of the evidence 
method of approval if the agency decided to create product-specific 
guidances.169 While using this method, the FDA considers “structural 
and functional characterization, nonclinical evaluation, human PK and 
PD data, clinical immunogenicity data, and comparative clinical 
study(ies) data.”170 These steps in analysis are required by both the 
FDA171 and EMA172 during the development stage of biosimilars. The 
FDA can continue to place greater weight on certain aspects of the ap-
proval process depending on the specificity of the biosimilar product. 
Creating product-specific guidances would not remove this feature of 
the FDA’s application considerations but will assist biosimilar spon-
sors to determine the specific data and analysis the FDA wants in as-
sessing the application.173 
The FDA can also continue to meet with biosimilar sponsors dur-
ing the approval process even though there will be less necessity for 
these meetings. The FDA already suggests that sponsors should con-
sider other sources of information applicable to their product develop-
ment prior to requesting a meeting with the FDA.174 The FDA’s main 
interest in making this request is to have sponsors be more efficient 
with FDA resources.175 If the FDA were to make product-class specific 
guidelines, the biosimilar sponsors would have more information 
available for what is necessary in their approval process. This would 
require less meetings with the FDA, allowing the agency to use the 
resources allotted to it for other purposes. When necessary, sponsors 
would still be able to meet with the FDA, especially if problems arise 
 
 167.  Wang & Chow, supra note 132, at 360. 
 168.  Id. at 361–362. 
 169.  See Christl, supra note 17, 19–20. The totality of the evidence method is used by 
FDA scientist to evaluate information from the sponsor. The method of the sponsor’s research 
is not dependent on this approach. 
 170.  U.S. FOOD & DRUG ADMIN., supra note 36, at 8. 
 171.  Id. 
 172.  Guideline on Similar Biological Medicinal Products, supra note 86. 
 173.  See infra note 168. 
 174.  OMB Control No. 0910-0802, supra note 129, at 7. 
 175.  Id. 
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during the application process.176  
IV.  CONCLUSION 
Five years since the passing of the BPCI Act, only four biosimi-
lars have been approved.177 The European Union and EMA have seen 
far greater success in biosimilar approval using a guidance approach 
and have had biosimilars on the market since 2006.178 The FDA instead 
has used a sponsor meeting approach which has left many biosimilar 
manufacturers lacking clarity. As long as there is uncertainty in what 
is required for biosimilar approval, development of biosimilars will be 
stymied. Although the FDA faces other barriers to approval of biosim-
ilars, including biologic patent extension179 and the cost of develop-
ment of biosimilars,180 providing further clarity to biosimilar sponsors 
will improve the approval process. Based on the EMA’s success in ap-
proving biosimilars, the best method of giving further clarity to bio-
similar sponsors is through product-specific guidances. Until the FDA 
can publish product-specific guidances, biosimilar sponsors will con-
tinue to have difficulty gaining approval. 
 
 
 176.  This would put greater emphasis on BPD Type 1 and Type 2 meetings, where spon-
sors need answers to actual questions to continue their application process.  OMB Control No. 
0910-0802, supra note 129, at 3–4. 
 177.  Information on Biosimilars, U.S. FOOD & DRUG ADMINISTRATION (Feb. 22, 2016), 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAp-
proved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars. 
 178.  European Public Assessment Reports, supra note 9. 
 179.  Erwin A. Blackstone & Joseph P. Fuhr, The Economics of Biosimilars, 6 AM. HEALTH 
& DRUG BENEFIT 469, 472 (2013). 
 180.  Id. at 470–71. A biosimilar costs between $100 million and $250 million to develop. 
Id. 
